Anti-tumor immune therapy with programmed death-1 and its ligand inhibitors: Research advances / 国际药学研究杂志

ABSTRACT

Programmed death-1 (PD-1) and its ligand (PD-L1) inhibitors are a novel kind of immune checkpoint blockers, which are the highlights of anti-tumor immune therapy. PD-1 inhibitors, such as nivolumab and pembrolizumab have been granted by the market authorization to treat melanoma and non-small cell lung cancer. Clinical trials of their efficacy and safety on renal cell carcinoma, bladder carcinoma and Hodgkin′s lymphoma are still in process. PD-L1 inhibitors atezolizumab, durvalumab and avelumab have been approved by FDA for treatment of urothelial carcinoma. Several other drugs are in phase I clinical trials. This paper gives a brief summary of recent advances in the studies on PD-1/PD-L1 inhibitors.